Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Bausch Gains 38.9% YTD On Product Launches & Debt Reduction

By Zacks Investment ResearchStock MarketsJul 05, 2019 08:35AM ET
Bausch Gains 38.9% YTD On Product Launches & Debt Reduction
By Zacks Investment Research   |  Jul 05, 2019 08:35AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Shares of Bausch Health Companies Inc. (NYSE:BHC) have rallied 38.9% in the year so far, outperforming the industry’s growth of 3.9%.

The company develops, manufactures and markets a wide range of branded, generic and over-the-counter (OTC) products. After a tumultuous period, it began a turnaround journey in 2018 and the efforts toward the same have been reaping encouraging results so far.

Bausch has narrowed its focus on seven recently launched or expected to be launched products, pending completion of testing and receipt of FDA approval. The products include Vyzulta, Siliq, Bryhali (psoriasis), Lumify, Duobrii, Relistor and SiHy Daily. Four of these seven products were launched in 2018. The company has other products in its pipeline as well.

A couple of product launches boosted investor sentiment last month. Bausch launched psoriasis lotion, Duobrii, in the United States. The FDA has approved Duobrii Lotion for the topical treatment of plaque psoriasis in adults in April 2019. The company already has Siliq in its portfolio for psoriasis.

Bausch also announced the U.S. launch of Bausch + Lomb ULTRA Multifocal for Astigmatism contact lenses for patients with both astigmatism and presbyopia.

Meanwhile, the Salix business continues to drive growth and contribute to the top line. In particular, increased sales of Xifaxan are boosting the segment. The company recently settled the Xifaxan IP litigation, which should preserve market exclusivity until 2028. The company also entered an exclusive agreement with Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) to co-promote Doptelet in the United States for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. The addition of Trulance from the Synergy acquisition has bolstered the franchise.

In the meantime, investors cheered Bausch’s announcement of clearing an additional $100 million of its senior secured term loans in June 2019, using cash generated from operations. This led the company to eliminate all mandatory amortization for the first quarter of 2020. The company’s efforts to sell non-core assets and clear huge levels of debt are commendable.

Though it is still difficult to comment on the slow rebuilding process, we expect the momentum to pick up gradually as Bausch strengthens its ophthalmology franchise and Salix business.

Zacks Rank & Other Stocks to Consider

Bausch currently carries a Zacks Rank #2 (Buy). A couple of other similar-ranked stocks from the same sector are Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) and Acasti Pharma, Inc. (NASDAQ:ACST) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Loss estimates for Adamas for 2019 have narrowed to $3.77 from $4.14 in the past 60 days.

Loss estimates for Acasti for 2021 have narrowed by 6 cents to 11 cents in the past 60 days.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report

Acasti Pharma, Inc. (ACST): Free Stock Analysis Report

Dova Pharmaceuticals, Inc. (DOVA): Free Stock Analysis Report

Bausch Health Cos Inc. (BHC): Free Stock Analysis Report

Original post
Bausch Gains 38.9% YTD On Product Launches & Debt Reduction

Related Articles

Tim Knight
Holy Frijoles By Tim Knight - May 20, 2022 3

I’ve never liked Chipotle (NYSE:CMG) food, and it’s heartening to see that about $800 has already been blown off of its absurd (former) $2,000/share price. I’d say it has precious...

Bausch Gains 38.9% YTD On Product Launches & Debt Reduction

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email